Sharemaestro company-news research for Roivant Sciences Ltd (ROIV), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Measured evidence
Company news sentiment
ROIV news sentiment
Roivant Sciences Ltd
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone44Neutral is 50
Balanced news tone
58/100 evidence confidence
100% direct company focus
3 current stories across 2 publishers
Current company news
Price moving ahead of tone
Balanced news tone is drawn from 3 fresh independent stories, including 3 company-specific items across 2 publishers.
Latest source headline Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History Yahoo! Finance Canada · 10 Aug 2026 11:56What supports the read
3 current stories are mapped specifically to ROIV.
Cross-story agreement is 91/100, indicating a comparatively coherent tape.
What tempers the read
Only 2 publishers currently contribute to the measured read.
Price is moving more forcefully than the current news tone suggests.
44/100
Weighted toneBalanced news tone
58/100
Evidence confidencebuilding confidence
100%/100
Company focus3 direct stories
91/100
Evidence agreement9/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth34
2.68 effective storiesSource breadth40
2 independent publishersDirect relevance100
company-specific evidence shareFreshness54
recency-weighted evidenceAgreement91
cross-story consistencySource independence34
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Price is moving more forcefully than the current news tone suggests.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
News subjects
What is shaping the score
Earnings352 stories · 67%
Market update501 stories · 33%
Source mix
Where the evidence comes from
finance.yahoo.com352 stories · 67%
Yahoo! Finance Canada501 stories · 33%
Recurring subjects
Subjects appearing most often
Earnings2Biotech2Shareholder1Share Price1Investment Risk1Healthcare1Clinical Trials1Balance Sheet1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#150Tone
Yahoo! Finance CanadaDirect company coverage
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History
- Published
- 10 Aug 2026 11:56
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#229Tone
finance.yahoo.comDirect company coverage
Is Roivant Sciences’ (ROIV) Cost Discipline Offsetting Slower Revenue Enough to Refresh Its Story?
Roivant Sciences reported past first-quarter 2026 results, with sales of US$1.44 million versus US$2.17 million a year earlier and a narrower net loss of US$189.84 million, reducing basic loss per share from US$0.33 to US$0.26. The combination of lower revenue yet improved loss per share highlights Roivant's ongoing effort to manage costs while progressing its inflammation and immunology portfolio. We'll now examine how this combination of reduced sales and a smaller quarterly net loss could reshape Roivant Sciences' broader investment narrative. Rare earth metals are an input to most high-tec
Balance SheetBiotechClinical TrialsEarningsInvestment Risk
- Published
- 09 Aug 2026 20:11
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#346Tone
finance.yahoo.comDirect company coverage
Is Roivant Sciences (ROIV) Overvalued On First Quarter Results?
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Roivant Sciences Stock Is In Focus After First Quarter Results Roivant Sciences (NasdaqGS:ROIV) is in focus after reporting first quarter results for the period ended June 30, 2026. Sales were US$1.44 million, while the company reported a net loss of US$189.84 million. The loss from continuing operations translated into a basic loss per share of US$0.26. Investors are now weighing how these figures, together with the updated loss profile, fit into the broader story for th
BiotechEarningsHealthcareShare PriceShareholder
- Published
- 09 Aug 2026 15:09
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Earlier company news
ROIV news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above.
Aug
02
2026
TradingViewArchivedNeutral tone
Roivant Sciences Ltd. Revenue Breakdown – NASDAQ:ROIV
- Published
- 2 Aug 2026 16:09
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
31
2026
TradingKeyArchivedNeutral tone
Roivant Sciences Ltd (ROIV) Financial Health: Profitability & Balance Sheet Analysis
- Published
- 31 Jul 2026 14:15
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
31
2026
Quiver QuantitativeArchivedNeutral tone
Roivant Sciences Ltd. ($ROIV) CEO 2025 Pay Revealed
- Published
- 31 Jul 2026 03:12
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
23
2026
GlobeNewswireArchivedNeutral tone
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
- Published
- 23 Jul 2026 23:18
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
23
2026
Investing.com IndiaArchivedNeutral tone
Form 4 Roivant Sciences Ltd. For: 21 July
- Published
- 23 Jul 2026 12:21
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
22
2026
Stock TitanArchivedNeutral tone
Roivant Sciences (ROIV) director awarded 405 fully vested shares
- Published
- 22 Jul 2026 03:52
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
19
2026
Kavout | AIArchivedPositive tone
Why is Billionaire Joe Edelman Bullish on Roivant Sciences (ROIV)
- Published
- 19 Jul 2026 01:43
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
16
2026
StockStoryArchivedPositive tone
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Published
- 16 Jul 2026 18:15
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
15
2026
Market sourceArchivedPositive tone
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Published
- 15 Jul 2026 12:06
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
12
2026
QuartrArchivedNeutral tone
Roivant Sciences (ROIV) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary
- Published
- 12 Jul 2026 00:14
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
11
2026
BioCenturyArchivedNeutral tone
Roivant’s Gline: From spin-cos to commercial conviction
- Published
- 11 Jul 2026 14:35
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
10
2026
Investing.comArchivedNeutral tone
Roivant Sciences stock hits all-time high at 35.92 USD
- Published
- 10 Jul 2026 05:57
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
08
2026
Investing.com CanadaArchivedNeutral tone
Roivant Sciences stock hits all-time high at 35.92 USD By Investing.com
- Published
- 8 Jul 2026 16:53
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
07
2026
Market sourceArchivedNeutral tone
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years?
- Published
- 7 Jul 2026 13:16
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
04
2026
Stock TitanArchivedNeutral tone
Roivant Sciences (ROIV) director exercises options, sells 10,000 common shares
- Published
- 4 Jul 2026 02:11
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
02
2026
simplywall.stArchivedNeutral tone
Roivant Sciences (ROIV) Left Key Russell Indexes, Is It Still 10% Below Fair Value?
- Published
- 2 Jul 2026 13:33
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
02
2026
Stock TitanArchivedNeutral tone
Roivant Sciences (ROIV) director sells 17,750 shares after exercising options
- Published
- 2 Jul 2026 07:56
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
30
2026
TradingViewArchivedPositive tone
Roivant Sciences President & CIO Sold Shares Worth Over $34M
- Published
- 30 Jun 2026 05:26
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
28
2026
TradingViewArchivedPositive tone
Enterprise value to EBITDA forward of Roivant Sciences Ltd. – DUS:87S
- Published
- 28 Jun 2026 00:22
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
26
2026
TradingViewArchivedPositive tone
Price to book forward of Roivant Sciences Ltd. – NASDAQ:ROIV
- Published
- 26 Jun 2026 12:14
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
25
2026
Investing.comArchivedPositive tone
Roivant Sciences stock hits all-time high at 32.8 USD
- Published
- 25 Jun 2026 08:03
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
23
2026
DirectorsTalk InterviewsArchivedPositive tone
Roivant Sciences Ltd. (ROIV) Stock Analysis: Navigating Biotech Opportunities with 24.22% Potential Upside
- Published
- 23 Jun 2026 23:02
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
22
2026
Simply Wall StreetArchivedPositive tone
What Roivant Sciences (ROIV)'s $2.25 Billion Moderna Settlement and Immunology Wins Mean For Shareholders
- Published
- 22 Jun 2026 22:11
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
20
2026
Simply Wall StreetArchivedPositive tone
Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress
- Published
- 20 Jun 2026 10:17
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.